Saw Palmetto Efficacy For BPH Symptoms Slated For NIH Clinical Study
This article was originally published in The Tan Sheet
Executive Summary
Three NIH divisions plan to spend a combined $29 mil. over the next seven years to study the efficacy of saw palmetto and Pygeum africanum on relieving symptoms associated with benign prostatic hyperplasia
You may also be interested in...
Saw Palmetto, BPH Study Backed By $1.6 Mil. In NIDDK Funding
Researchers at the University of California-San Francisco expect to complete enrollment for a study on the effects of saw palmetto in alleviating symptoms of benign prostatic hyperplasia (BPH) in June
Saw palmetto
Patients treated with botanical for six months had 32% decrease in dihydrotestosterone (DHT), a hormone associated with benign prostatic hyperplasia, researchers report in June Urology. Leonard Marks, UCLA School of Medicine, et al., randomized 44 men with symptomatic BPH to either 320 mg/day saw palmetto or placebo. Researchers took right and left mid-saggittal biopsy cores from each patient at baseline and after six months. Ongoing randomized, placebo-controlled trial funded by Urological Sciences Research Foundation and Alticor division Nutriline
Saw Palmetto "Moderate" Quality Evidence Shows BPH Symptom Relief - USP
The U.S. Pharmacopeia's final monograph on saw palmetto lists 10 published studies on the ingredient that met the USP quality standard of Level II or higher, under the organization's new criteria for evidence submission for botanicals.